Table 2.
Follow-up and clinical outcome
| Clinical outcome | |||||
|---|---|---|---|---|---|
| Parameters | Pilot phase n = 32 | Validation phase n = 115 | |||
| Relapse n = 16 | Control n = 16 | Relapse n = 30 | Control n = 85 | ||
| Time to local relapse (months) | Median | 37 | x | 74 | x |
| Range | 15–123 | x | 35–185 | x | |
| Time to distant metastasis (months) | Median | 61 | x | 70 | 49.5 |
| Range | 20–96 | x | 27–118 | 9–109 | |
| Follow-up (months) | Median | 121.5 | 130.5 | 125 | 140 |
| Range | 26–192 | 72–200 | 44–214 | 17–207 | |
| Lost to follow-up (n) | 0 | 0 | 0 | 1 (1.2 %) | |
| Cancer specific deaths (n) | 4 (25 %) | 0 | 7 (23.3 %) | 2 (2.4 %) | |
Summary follow-up and clinical outcome in the pilot and validation phases